Glaucomatous neurodegeneration: An eye on tumor necrosis factor-alpha

Indian Journal of Ophthalmology

Volumn 60, Issue 4, 2012, Pages 255-261

  Agarwal, Renu ^a   Agarwal, Puneet ^b  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Apoptosis; glaucoma; intraocular pressure; retinal ganglion cells; retinal ischemia; tumor necrosis factor alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BIOSYNTHESIS; DISEASE COURSE; GLAUCOMA; HUMAN; METABOLISM; OPTIC NERVE DISEASE; PATHOLOGY; RETINA GANGLION CELL; REVIEW;

APOPTOSIS; DISEASE PROGRESSION; GLAUCOMA; HUMANS; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864419059     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.98700     Document Type: Review

References (82)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93.
2. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51.
3. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20.
4. Aggarwal BB. Signaling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 2003;3:745-56.
5. Tracey K, Cerami A. Metabolic Response to Cachectin/TNF. In: Boland B, Cullinan J, Kimball C, editors. Annals of the New York Academy of Sciences. New York: New York Academy of Sciences; 1990. p. 325-30.
6. Janeway C, Travers P, Walport M, Capra J. Immunobiology : The Immune System in Health and Disease. New York: Garland Publishers; 1999.
7. Strieter R, Kunkel S, Bone R. Role of Tumor Necrosis Factor-Alpha in Disease States and Inflammation. Crit Care Med 1993;21:S447-63.
8. Rink L, Kirchner H. Recent Progress in the Tumor Necrosis Factor-Alpha Field. Int Arch Allergy Immunol 1996;111:199-209.
9. Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 2001;22: 873-83.
10. Nagatsu T. Sawada M. Inammatory process in Parkinson's disease: Role for cytokines. Curr Pharm Des 2005;11:999-1016.
11. Comabella M, Romera C, Camina M, Perkal H, Moro MA, Leza JC, et al. TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. J Neurol 2006;253:701-6.
12. Cheng B, Christakos S, Mattson MP. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994;12:139-53.
13. Hermann GE, Rogers RC, Bresnahan JC, Beattie MS. Tumor necrosis factor-alpha induces cFOS and strongly potentiates glutamate-mediated cell death in the rat spinal cord. Neurobiol Dis 2001;8:590-9.
14. Sawada H, Fukuchi T, Tanaka T, Abe H. Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci 2010;51:903-6.
15. Huang P, Qi Y, Xu YS, Liu J, Liao D, Zhang SSM, et al. Serum Cytokine Alteration is Associated with Optic Neuropathy in Human Primary Open Angle Glaucoma. J Glaucoma 2010;19: 324-30.
16. Madigan MC, Sadun AA, Rao NS, Dugel PU, Tenhula WN, Gill PS. Tumor necrosis factor-alpha (TNF-alpha)-induced optic neuropathy in rabbits. Neurol Res 1996;18:176-84.
17. Kitaoka Y, Kitaoka Y, Kwong JM, Ross-Cisneros FN, Wang J, Tsai RK, et al. TNF-aí-Induced Optic Nerve Degeneration and Nuclear Factor-êB p65. Invest Ophthalmol Vis Sci 2006;47:1448-57.
18. Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H, et al. Tumor Necrosis Factor-aí Mediates Oligodendrocyte Death and Delayed Retinal Ganglion Cell Loss in a Mouse Model of Glaucoma. J Neurosci 2006;26:12633-41.
19. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol 2000;118:666-73.
20. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: A potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia 2000;32:42-50.
21. Yang Z, Quigley HA, Pease ME, Yang Y, Qian J, Valenta D, et al. Changes in Gene Expression in Experimental Glaucoma and Optic Nerve Transection: The Equilibrium between Protective and Detrimental Mechanisms. Invest Ophthalmol Vis Sci 2007,48; 5539-48.
22. Fuchs C, Forster V, Balse E, Sahel JA, Picaud S, Tessier LH. Retinal-Cell-Conditioned Medium Prevents TNF-{alpha}-Induced Apoptosis of Purified Ganglion Cells. Invest Ophthalmol Vis Sci 2005;46:2983-91.
23. Tezel G, Wax MB. Increased production of tumor necrosis factoralpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 2000;20:8693-700.
24. Yuan L, Neufeld AH. Activated microglia in the human glaumatous optic nerve head. J Neurosci Res 2001;64:523-32.
25. Levkovitch VH, Dardik R, Vander S, Nisgav Y, Kalev-Landoy M, Melamed S. Experimental glaucoma and optic nerve transaction induce simultaneous upregulation of pro apoptotic and prosurvival genes. Invest Ophthalmol Vis Sci 2006;47:2491-7.
26. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome C by direct inhibition of distinct caspases. EMBO J 1998;17:2215-23.
27. Deveraux QL, Stennicke HR, Salvesen GS, Reed JC. Endogenous inhibitors of caspases. J Clin Immunol 1999;19:388-98.
28. Perrelet D, Ferri A, MacKenzie AE, Smith GM, Korneluk RG, Liston P, et al. IAP family proteins delay motoneuron cell death in vivo. Eur J Neurosci 2000;12:2059-67.
29. McPhail LT, Vanderluit JL, McBride CB, Oschipok LW, Crocker SJ, Xu D, et al. Endogenous expression of inhibitor of apoptosis proteins in facial motoneurons of neonatal and adult rats following axotomy. Neurosci 2003;117:567-75.
30. Bai Y, Shi Z, Zhuo Y, Liu J, Malakhov A, Ko E, et al. In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death. Invest Ophthalmol Vis Sci 2010;51:6639-51.
31. Tezel G, Li LY, Patil RV, Wax MB. TNF-aí and TNF-aí Receptor-1 in the Retina of Normal and Glaucomatous Eyes. Invest Ophthalmol Vis Sci 2001;42:1787-94.
32. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002;22:1-7.
33. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-9.
34. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 1997;91:231-41.
35. Marchetti L, Klein M, Schlett KP, Zenmaier K, Eisel UL. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamateinduced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 2004;279:32869-81.
36. Lawlor MA, Alessi DR. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001;114:2903-10.
37. Rothe M, Sharma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 1995;269:1424-7.
38. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999;283:543-6.
39. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995;81:495-504.
40. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996;84:299-308.
41. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/ APO-1-and TNF receptor-induced cell death. Cell 1996;85:803-15.
42. Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J 1996;15:6189-96.
43. Barnes PJ, Karin M. Nuclear factor-?B: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
44. Karin M. Liu ZG, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-6.
45. Beg AA, Baltimore D. An Essential Role for NF-êB in Preventing TNF-aí-Induced Cell Death. Science 1996;274:782-4.
46. Crisanti P, Leon A, Lim DM, Omri B. Aspirin prevention of NMDAinduced neuronal death by direct protein kinase C? inhibition. J Neurochem 2005;93:1587-93.
47. Diaz-Meco MT, Municio MM, Sanchez P, Lozano J, Moscat J. Lambda-interacting protein, a novel protein that specifically interacts with the zinc finger domain of the atypical protein kinase C isotype lambda/iota and stimulates its kinase activity in vitro and in vivo. Mol Cell Biol 1996;16:105-14.
48. Liang H, Baudouin C, Behar-Cohen F, Cristani P, Omri B. Protein kinase C-zeta mediates retinal degeneration in response to TNF. J Neuroimmunol 2007;183:104-10.
49. Yeh WC, de la Pompa L, Elia AJ, Shahinian A, Ng M, Mitchell K, et al. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998;279:1954-8.
50. Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol 1999;19:350-64.
51. Smith L, Smith JB. Lack of constitutive activity of the free kinase domain of protein kinase C zeta. Dependence on transphosphorylation of the activation loop. J Biol Chem 2002;277:45866-73.
52. Xiaohong Z, Feng L, Li K, Hiroshi T, Chao L, Wei C. Involvement of Inflammation, Degradation, and Apoptosis in a Mouse Model of Glaucoma. J Biol Chem 2005;280:31240-48.
53. Tezel G, Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest Ophthalmol Vis Sci 2004;45: 4049-59.
54. Bachelder RE, Wendt MA, Fujita N, Tsuruo T, Mercuriob AM. The Cleavage of Akt/Protein Kinase B by Death Receptor Signaling Is an Important Event in Detachment-induced Apoptosis. J Biol Chem 2001;276:34702-7.
55. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002;295:1077-9.
56. Li Y, Kang J, Horwitz MS. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alphainducible cellular protein containing leucine zipper domains. Mol Cell Biol 1998;18:1601-10.
57. Zhu G, Wu CJ, Zhao Y, Ashwell JD. Optineurin negatively regulates TNFalpha-induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP. Curr Biol 2007;17:1438-43.
58. Chalasani ML, Gupta RV, Agarwal N, Balasubramanian D, Swarup G. A Glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by antioxidants. Invest Ophthalmol Vis Sci 2007;48:1607-14.
59. Fan BJ, Liu K, Wang DY, Tham CC, Tam PO, Lam DS, et al. Association of polymorphisms of tumor necrosis factor and tumor protein p53 with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2010;51:4110-6.
60. Khan MI, Micheal S, Rana N, Akhtar F, den Hollander AI, Ahmed A, et al. Association of tumor necrosis factor alpha gene polymorphism G-308A with pseudoexfoliative glaucoma in the Pakistani population. Mol Vis 2009;15:2861-7.
61. Razeghinejad MR, Rahat F, Kamali-Sarvestani E. Association of TNFA -308 G/A and TNFR1 +36 A/G gene polymorphisms with glaucoma. Ophthalmic Res 2009;42:118-24.
62. Tekeli O, Turacli ME, Egin Y, Akar N, Elhan AH. Tumor necrosis factor alpha-308 gene polymorphism and pseudoexfoliation glaucoma. Mol Vis 2008;14:1815-8.
63. Mossböck G, Renner W, El-Shabrawi Y, Faschinger C, Schmut O, Wedrich A, et al. TNF-a -308 G>A and -238 G>A polymorphisms are not major risk factors in Caucasian patients with exfoliation glaucoma. Mol Vis 2009;15:518-22.
64. Diem R, Meyer R, Weishaupt JH, Bahr M. Reduction of potassium currents and phosphatidylinositol 3-kinase-dependent AKT phosphorylation by tumor necrosis factor-(alpha) rescues axotomized retinal ganglion cells from retrograde cell death in vivo. J Neurosci 2001;21:2058-66.
65. Shafer RA, Murphy S. Activated astrocytes induce nitric oxide synthase-2 in cerebral endothelium via tumor necrosis factor a. Glia 1998;21:370-9.
66. Goureau, O, Amiot F, Dautry F, Courtois Y. Control of nitric oxide production by endogenous TNF-alpha in mouse retinal pigmented epithelial and Muller glial cells. Biochem Biophys Res Commun 1997;240:132-5.
67. Toda N, Toda MN. Nitric oxide: Ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res 2007;26:205-38.
68. Neufeld AH. Nitric oxide: A potential mediator of retinal ganglion damage in glaucoma. Surv Ophthalmol 1999;43:S129-35.
69. Chae IH, Park KW, Kim HS, Oh BH. Nitric oxide-induced apoptosis is mediated by Bax/Bcl-2 gene expression, transition of cytochrome c, and activation of caspase-3 in rat vascular smooth muscle cells. Clin Chim Acta 2004;341:83-91.
70. Narayan S, Prasanna G, Krishnamoorthy RR, Zhang X, Yorio T. Endothelin-1 Synthesis and Secretion in Human Retinal Pigment Epithelial Cells (ARPE-19): Differential Regulation by Cholinergics and TNF-a. Invest Ophthalmol Vis Sci 2003;44:4885-94.
71. Desai D, Shaoqing H, Thomas Y, Krishnamoorthy RR, Ganesh P. Hypoxia augments TNF-alpha-mediated endothelin-1 release and cell proliferation in human optic nerve head astrocytes. Biochem Biophys Res Commun 2004;4:318:642-8.
72. Prasanna G, Krishnamoorthy R, Hulet C, Zhang H, Zhang X, Yorio T. Endothelin-1 induces nitric oxide synthase-2 expression in human non-pigmented ciliary epithelial cells. Exp Eye Res 2000;71:535-9.
73. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol 1997;115:497-503.
74. Noske W, Hensen J, Wiederholt M. Endothelin-like immunoreactivity in aqueous humor of primary open-angle glaucoma and cataract patients. Graefes Arch Clin Exp Ophthalmol 1997;235:551-2.
75. Sugiyama T, Moriya S, Oku H, Azuma I. Association of endothelin-1 with normal tension glaucoma: Clinical and fundamental studies. Surv Ophthalmol 1995;39:S49-56.
76. Shaoqing H, Ganesh P, Thomas Y. Endothelin-1-mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes. Invest Ophthalmol Vis Sci 2007;48:3737-45.
77. Fr?d?ric LJ, Mathieu JB, Olivier DB, David S, Carlos RM, Adriana DP, et al. ProNGF induces TNFa-dependent death of retinal ganglion cells through a p75NTR non-cell autonomous signaling pathway. Proc Natl Acad Sci U S A 2010;107:3817-22.
78. Bai Y, Dergham P, Nedev H, Xu J, Galan A, Rivera JC, et al. Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. J Biol Chem 2010;285:39392-400.
79. Hong S, Kim CY, Lee JE, Seong GJ. Agmatine protects cultured retinal ganglion cells from tumor necrosis factor-alpha-induced apoptosis. Life Sci 2009;84:28-32
80. Wang WP, Iyo AH, Miguel-Hidalgo J, Regunathan S, Zhu MY. Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res 2006;1084:210-6.
81. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: An endogenous clonidine-displacing substance in the brain. Science 1994;263:966-9.
82. Reis DJ, Regunathan S. Agmatine: An endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann N Y Acad Sci 1999;881:65-80.